Autopsy report · NCT01073852

Hydroxychloroquine Efficacy in Chronic Urticaria

“withdrawn, not funded”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Vanderbilt University

Sponsor type

University, hospital or other

Conditions

Chronic Urticaria

Interventions

Placebo; Hydroxychloroquine

Participants

0

Trials that died the same way

• Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy
  “Funding withdrawn” (92% match in meaning)
• The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU
  “Withdrawn due to no funding” (92% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (90% match in meaning)
• MAGIK for Femoral/Tibial Shaft Fractures
  “Withdrawn due to lack of funding.” (86% match in meaning)
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
  “Funding withdrawal” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.